
Publication|Articles|September 16, 2026
Pharmacy Practice in Focus: Health Systems
- September 2026
- Volume 15
- Issue 5
Direct Oral Anticoagulants: Safety Profile and the Pharmacist’s Role
Fact checked by: Ron Panarotti
Pharmacists are well equipped to manage DOAC therapy by providing initial education, adherence support, and safety monitoring.
Advertisement
Advertisement
Pharmacists play a vital role in delivering high-quality cardiovascular care, particularly in managing anticoagulation therapy. Anticoagulants are prescribed for over 8 million patients across the United States to manage thromboembolisms.1 The Institute for Safe Medication Practices classifies antithrombotic agents as high-risk medications due to their serious adverse events; however, subtherapeutic dosing carries significant morbidity and mortality risk due to thromboembolic complications.2
Related to this article

A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.

October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.

CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.

Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.

From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.

Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.

A current pharmacy resident provides insights on how pharmacy students can manage the transition from student to resident.
Advertisement
Advertisement

